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Preanalytical confounding factors 
in the analysis of cerebrospinal 
fluid biomarkers for Alzheimer’s 
disease: the issue of diurnal 
variation
Claudia Cicognola, Davide Chiasserini and Lucilla Parnetti *
Section of Neurology, Department of Medicine, Centre for Memory Disturbances, University of Perugia, Perugia, Italy
Given the growing use of cerebrospinal fluid (CSF) beta-amyloid (Aβ) and tau as biomarkers 
for early diagnosis of Alzheimer’s disease (AD), it is essential that the diagnostic procedures 
are standardized and the results comparable across different laboratories. Preanalytical 
factors are reported to be the cause of at least 50% of the total variability. Among them, 
diurnal variability is a key issue and may have an impact on the comparability of the 
values obtained. The available studies on this issue are not conclusive so far. Fluctuations 
of CSF biomarkers in young healthy volunteers have been previously reported, while 
subsequent studies have not confirmed those observations in older subjects, the ones 
most likely to receive this test. The observed differences in circadian rhythms need to 
be further assessed not only in classical CSF biomarkers but also in novel forthcoming 
biomarkers. In this review, the existing data on the issue of diurnal variations of CSF 
classical biomarkers for AD will be analyzed, also evaluating the available data on new 
possible biomarkers.
Keywords: cerebrospinal fluid, biomarkers, diurnal variability, circadian rhythm, confounding factors, Alzheimer’s 
disease
Relevance of CSF Biomarkers in Clinical Practice
In the past few years, the diagnostic criteria for Alzheimer’s disease (AD) have gone through 
several rearrangements. According to the International Working Group (IWG) for New Research 
Criteria for the Diagnosis of Alzheimer’s Disease, both cerebrospinal fluid (CSF) and imaging 
biomarkers have been recognized as mandatory for detection of AD predementia phases. The 
same priority has been considered in the National Institute on Aging–Alzheimer’s Association 
(NIA–AA) criteria (1, 2). IWG criteria subdivide clinically manifest AD in prodromal AD and 
AD dementia, based on whether episodic memory loss or other cognitive symptoms prevent the 
subject from accomplishing the instrumental activities of daily living (IADL) or not. If any AD 
biomarker (CSF or imaging) is abnormal, this is sufficient to fulfill the biomarker criterion for AD. 
The NIA-AA criteria make a distinction between amyloid markers and neuronal injury markers 
(tau): the likelihood of preclinical stage and MCI diagnosis is dependent on how many of the 
markers are positive, where amyloid is the earliest to become positive. The IWG and NIA-AA 
criteria share the concept of a preclinical stage of the disease, which can be recognized before 
dementia onset, and highlight the need of AD biomarkers both for diagnosing the disease in early 
stages and for supporting the diagnosis in clinically overt pathology (Table 1).
TABLe 1 | Differences between iwG and NiA-AA criteria for AD.
Stages Cognitive criteria Biomarker criteria
iwG NiA-AA iwG NiA-AA iwG NiA-AA
Prodromal 
AD
MCI due 
to AD
Memory 
impairment
MCI Any amyloid 
or injury 
marker
Likelihood:
• High: amyloid 
and injury 
marker both +
• Intermediate: 
one marker +, 
unknown the 
other
• Uninformative: 
one marker +, 
- the other
AD 
dementia
Dementia 
due to 
AD
Memory 
impairment
Dementia Any amyloid 
or injury 
marker
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The diagnostic value of biomarkers has been even more 
strengthened in the IWG-2 criteria (3). In these criteria, a 
simplified diagnostic algorithm based on CSF molecular AD 
phenotype or amyloid imaging was proposed. The algorithm 
consisted of decreased Aβ levels together with increased t-tau 
or p-tau concentrations, or an increased retention on amyloid 
PET tracer. CSF pathophysiological markers for AD include 
the beta-amyloid peptide 1–42 (Aβ42), which shows lower 
CSF levels the more the brain carries amyloid burden, total tau 
(t-tau), which directly reflects the intensity of neuronal degenera-
tion, and phosphorylated tau (p-tau), which is believed to be 
a direct marker of tangle pathology (4). In an autopsy cohort, 
low CSF Aβ42 concentrations had a sensitivity of 96.4% for 
AD detection (5) and CSF markers significantly increased the 
diagnostic accuracy in clinically uncertain cases (6). However, 
low CSF levels of Aβ42 are not specific enough to diagnose AD, 
since they can also be found in non-AD dementias (Lewy body 
disease or vascular dementia) (7). A valuable tool for increas-
ing the diagnostic performance of Aβ42 is the Aβ42/40 ratio, 
which proved to be more reliable than Aβ42 alone in providing 
comprehensive information on the total Aβ load in the brain. A 
marked reduction in CSF Aβ42 and in the Aβ42/Aβ40 ratio has 
consistently been found in patients at different stages of AD (4, 
8, 9), and it can help in differentiating AD from non-AD forms, 
where the combination of the three classical biomarkers is of 
limited diagnostic value (10).
Several studies have shown that the combination of CSF bio-
markers may improve their global diagnostic accuracy (11–15). 
Data so far indicate that the combination of Aβ42 with either 
t-tau or p-tau has the best specificity. Additionally, the combined 
analysis of the CSF biomarkers provides a more accurate differ-
ential diagnosis between AD and other degenerative dementias. 
Aβ42 and tau (t-tau or p-tau) should be used in combination, 
and the simultaneous presence of low Aβ42 and high t-tau or 
p-tau concentrations strongly suggests an AD diagnosis even at 
a prodromal stage, with a sensitivity of 90–95% and a specificity 
of about 90% (16–20).
The importance to have reliable CSF biomarkers relies in the 
need to validate the clinical diagnosis with a biological correlate. 
Unfortunately, the results obtained in research studies are not yet 
totally supported by significant outcomes in routine clinical use of 
CSF biomarkers. Additional testing, including CSF analysis, has 
still little diagnostic impact in the diagnostic work-up on patients 
suspected to suffer AD-dementia, being rather more useful in 
patients with an initial non-AD dementia diagnosis (21). Reliable 
biomarkers are needed not only to confirm a clinical suspect but 
also to allow an early diagnosis, which is vital in order to prevent 
severe clinical manifestations by starting, as soon as possible, 
the disease-modifying therapies that are being developed and 
will be hopefully available in a near future. To this purpose, the 
new algorithm proposed by Lewczuk et al. (22) for diagnosing 
preclinical patients has further validated the diagnostic value 
of CSF biomarkers. The algorithm introduced the concept of 
“border zones” by taking into account not only the mere altera-
tion of the biomarkers but also the extent of the alteration, from 
slight to clearly pathologic. This may allow the subdivision of 
subjects into different groups according to the CSF pattern: no 
evidence for CNS disease, AD improbable, AD possible, and AD 
probable. The results obtained with this classification may allow 
a better coding of the CSF patterns not clearly pathologic when 
classified using IWG and NIA-AA criteria. This means that the 
CSF profile is a valuable diagnostic tool, even in the absence of 
clinical symptoms.
The issue of Standardization of CSF AD 
Biomarkers for Routine Clinical Use
Even if the strong correlation between positive CSF AD biomarkers 
and AD pathology has been widely demonstrated, defining which 
patients are candidates to undergo lumbar puncture and AD CSF 
biomarkers analysis is a critical step for several reasons. Most of 
the AD patients are diagnosed using only clinical criteria, but a 
high number of patients do not ultimately have underlying AD 
pathology. The proportion of misdiagnosed patients is even higher 
in cases of early onset AD, atypical presentations, or dementia with 
mixed etiologies. It is also necessary to optimize the diagnosis 
of non-amnestic presentations and differentiate AD pathology 
from other neurodegenerative disorders, i.e., dementia with Lewy 
bodies, fronto-temporal dementia, vascular dementia, psychiatric 
conditions etc. The last consensus (2014) from the Alzheimer’s 
Biomarkers Standardization Initiative (ABSI) (23) focused on the 
issues regarding clinical use of CSF biomarkers, and stated that 
patients in whom AD is part of the differential diagnosis may be 
candidates for lumbar puncture and CSF biomarkers analysis to 
increase specificity and minimize diagnostic errors. Given also 
the importance of early diagnosis, any patient with minimal but 
objective symptoms suggestive of AD is an appropriate candidate. 
CSF biomarkers analysis should be considered in all patients with 
early onset dementia, minimal or mild cognitive impairment, and 
atypical clinical presentation or complex differential diagnosis.
With these premises, it is clear that there is a major need for 
standardization in the CSF analysis procedures. Standardized 
protocols for biobanking are a prerequisite to guarantee that 
biomarker studies will not be influenced by preanalytical and 
analytical factors. One of the most important implications of 
biomarker standardization is to find univocal cut-off values for 
CSF biomarkers between and within laboratories, given that, even 
when using the same assay, significant variability has been found 
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in the absolute concentrations of AD biomarkers (24). In 2009, the 
Alzheimer’s Association started an international quality control 
(QC) program for CSF biomarkers (25). The aim of the program 
is to monitor, in a large network of laboratories all around the 
world, total analytical variability of CSF Aβ and tau, in order to 
identify the sources of variation and improve the standardization 
of the assays. All sources of variability (within-assay run, within/
between-laboratory, within/between-assay kit lot) were considered, 
along with the variability coming from bias, systematic deviation 
from a reference value, imprecision and random deviation from a 
value. The overall variability was generally around 20–30%, with 
a small contribution of within-run variability (5%–10%). Within-
laboratory longitudinal variability was higher, with a coefficient of 
variation (CV) of 5–19%. The main cause of the overall variability 
in the analysis of variance was the between-laboratory variability 
(19–28%). Even when the laboratory protocols and checklists were 
strictly followed, not a single factor was identified as the main 
source of variability. This led to the conclusion that laboratories 
can only be more accurate in following published guidelines (26). 
Moreover, it is critically important that kit manufacturers minimize 
lot-to-lot variations, to allow a broader use of these assays in the 
clinical setting. For now, the overall variability is still too high to 
allow the definition of univocal biomarker cut-off values; therefore, 
each laboratory should have internally qualified cut-off levels to 
guarantee optimal reproducibility over time.
Preanalytical Confounding Factors of  
CSF Biomarkers
Preanalytical factors are one of the main concerns in biochemical 
analysis, since they are responsible for about 40–60% of total labo-
ratory variability (27). In previous meetings of the aforementioned 
ABSI, the preanalytical issues affecting Aβ and tau in CSF were 
discussed, and they came up with guidelines for CSF collection, 
storage, and analysis. Some aspects were identified as key issues 
for samples collection and analysis, for example, a possible CSF 
concentration gradient of the biomarkers. Brain-derived proteins 
often show a decreasing rostro-caudal gradient, implying that 
the volume of CSF withdrawn can alter the concentration of 
the proteins analyzed. Studies showed that AD CSF biomarkers 
concentrations are not significantly influenced by fractionated 
sampling, therefore gradient effect does not represent an issue in 
this circumstance (28). Other biomarkers can be affected, such as 
α-synuclein (29); therefore, a standardized volume of CSF collec-
tion (12 ml) is recommended (30). CSF for diagnostic purposes is 
usually obtained by lumbar puncture between the L3/L4 and L4/
L5 intervertebral space, and a 22G atraumatic needle should be 
preferred to lower the risk of post-lumbar puncture headache (30). 
Moreover, a traumatic lumbar puncture increases the risk of blood 
contamination of the CSF sample; therefore, it is recommended to 
discard the first 1–2 ml to avoid any effect due to hemolysis and 
immediately centrifuge the sample before freezing (31). Some CSF 
analytes (for example, glucose) can be affected by meal consump-
tion, making fasting a prerequisite for sampling, but this can be 
a problematic request in elderly patients with an AD suspect. Aβ 
levels in plasma proved to be stable and not influenced by the 
patient’s food intake (32); therefore, there is no clear evidence that 
meal consumption affects CSF biomarker levels and so fasting is 
not a requirement for the analysis. Other preanalytical confound-
ing factors concern laboratory procedures regarding collection and 
storage of the samples. Aβ peptides can bind non-specifically to 
non-polypropylene (PP) collection tubes, leading to lower values 
in measured concentrations. Therefore, PP tubes are the recom-
mended standard for CSF samples collection and testing in routine 
clinical practice; each laboratory should always use the same PP 
tube, since different tubes may have a different adsorption level for 
the analytes (28). Vanderstichele et al. also recommended to aliquot 
the samples in small volumes (0.25 or 0.5 ml tube) and fill the tube 
up to 75%, to minimize the risk of adsorption and evaporation (28). 
However, a recent study by Willemse et al. showed no evaporation 
of CSF stored in biobanking tubes at –80°C or –20°C over a time 
span of 2 years (33). As mentioned, centrifugation of CSF samples 
is often performed, especially in the case of hemorrhagic lumbar 
punctures. However, the guidelines of Vanderstichele et al. pointed 
out no differences in classic biomarkers levels between centrifuged 
versus non-centrifuged samples (29). Nevertheless, the speed 
and temperature of centrifugation may be considerably different 
across laboratories; therefore, the consensus paper by Teunissen 
et al. recommended to centrifuge the hemorrhagic samples at a 
speed of 2000  × g for 10 min at room temperature (26). Time and 
temperature of storage may have a remarkable influence on the 
biomarkers levels, given their effects on serum and plasma proteins 
showed in proteomics studies (34). Vanderstichele et al. reported 
no significant effects on Aβ42, t-tau, and p-tau levels when the 
samples are left at room temperature for 5 days after CSF collection 
with respect to samples frozen immediately after collection (28). 
The recommendation is to keep the samples at 4°C for no longer 
than 5 days to avoid alterations of the final biochemical results (28). 
Different methods of freezing and storage do not cause significant 
variability in the results (32), but the freezing temperature of –80°C 
should be preferred for long-term storage (28). Few studies have 
been published regarding the stability of Aβ42, t-tau, and p-tau in 
CSF when stored frozen at –20°C or –80°C for many years, but this 
is an important issue in view of longitudinal studies. Vanderstichele 
et  al. did not observe changes in stability for up to 10 years at 
–80°C, but the recommendation is not to go beyond 2 months of 
storage at –20°C, as this is considered a sufficiently long time to run 
the analysis (28). The number of freeze/thaw cycles is a matter of 
concern since it can affect CSF biomarkers and lead to significant 
losses in Aβ concentrations (35). Recent studies, however, showed 
no significant alteration in the level of Aβ42 when CSF underwent 
more than one freeze/thaw cycle (32). However, freeze/thaw cycles 
should not be more than two and CSF must be aliquoted in small 
volumes; every change in the number of the freeze/thaw cycles 
must be accurately documented (28). The recommendations for 
CSF collection and storage are summarized in Table 2.
Circadian Rhythm
Among all the preanalytical confounding factors mentioned 
before, diurnal variation may play an important role as a source 
of variability. Circadian rhythm is involved in several physiologic 
processes, so it is reasonable to hypothesize its influence even 
in CSF biomarkers metabolism. Diurnal variation physiology 
must be analyzed more deeply, beginning from a review on the 
TABLe 2 | Summary of recommendations for preanalytical aspects of AD 
biomarker testing in CSF.
Possible variability factor Recommendation
CSF gradient No gradient observed 
Lumbar puncture L3–L4 or L4–L5
22G atraumatic needle to reduce the risk of 
blood contamination
Fasting Not required
Tubes PP (polypropylene)
Aliquotation Aliquot the samples in small volumes (0.25 or 
0.5 ml tube)
Fill the tube up to 75%
Centrifugation 2000 × g for 10 min at room temperature
Time before storage Up to 5 days
Temperature before storage 4°C
Freezing –80°C
–20°C for no longer than 2 months
Freeze/thaw cycles No more than 1–2
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anatomy of this ‘‘inner clock’’ that controls a large number of 
bodily functions.
Physiological Aspects
The suprachiasmatic nucleus (SCN) has a central role in the 
circadian rhythm system, together with its three primary afferent 
connections (36); the most important is the retino-hypothalamic 
projection through which information coming from rod/cone 
photoreceptors and retinal ganglion cells reaches the “inner 
clock.” The other two afferent connections consist of the median 
raphe serotonergic pathway and the geniculohypothalamic (GHT) 
pathway from the thalamic intergeniculate leaflet (IGL). Though 
this network might seem elementary, the several interconnections 
between the pathways make it complex and convoluted. When 
SCN is destroyed, a wide range of bodily functions loses its daily 
rhythms: sleep–wake, locomotor activity, feeding, drinking, body 
temperature, and secretion of hormones (37). These observations 
were confirmed by SCN transplantation studies in which the 
transplant restored the lost daily rhythms (38).
One of the best-known circadian pathways is the adrenal gland 
axis, as glucocorticoids proved to be a humoral entraining signal 
for peripheral clocks (39). Rhythmic glucocorticoids release is 
controlled peripherally by sympathetic stimuli and centrally by 
the SNC, through the secretion of corticotropin releasing hormone 
(CRH) and ACTH (40). Behavioral processes are also under the 
control of the SCN, such as locomotor activity and feeding. These 
behaviors can be entraining factors for the “inner clock,” therefore 
influencing endocrine function and body temperature.
Dysfunction of circadian rhythms has been shown to have a 
pathogenic role in several diseases, such as cancer and autoim-
mune diseases. Circadian rhythm disruption may play a role not 
only in the etiology but also in the progression of the clinical 
picture. This could be a consequence of the reciprocal relation-
ship between the neuroendocrine system and proinflammatory 
cytokines involved in the pathological process (41, 42). Moreover, 
this imbalance can act much earlier in the natural history of 
the disease; in fact, alterations in sleeping and eating patterns in 
humans were found to be a source of predisposition to metabolic 
and cardiovascular diseases (41). A diurnal variation of the 
symptoms is also typical of many diseases with an immune or 
inflammatory component. For example, in rheumatoid arthritis, 
patients refer more joint pain and stiffness in the morning hours, 
whereas patients with osteoarthritis refer a pain that increases 
through the day (41).
Circadian Rhythms in AD
Many of the physiological bodily functions described become 
impaired in AD, but also in other neurodegenerative disorders 
such as Parkinson’s disease and Huntington’s disease. In these 
conditions, several brain areas are affected by neurodegenerative 
processes, including the nuclei involved in circadian regulation. 
Neurodegenerative disorders are associated with several sleep–
wake rhythm disturbances, such as insomnia/hypersomnia, 
parasomnia, excessive nocturnal motor activity (for example, 
restless legs syndrome), and sleep apnea. In AD, sleep is often 
irregular and disturbed by multiple awakenings and, along with 
disease duration and progression to advanced stage, a phase shift 
of the sleep period is observed, often leading to a complete reversal 
of the day/night pattern (43). These signs and symptoms not only 
contribute to morbidity, poor quality of life, and institutionaliza-
tion of individuals with AD (44) but could also be involved in the 
etiology of the pathological process (45).
Changes in rest-activity patterns correlate with the severity of 
dementia and could be a preclinical marker, in healthy subjects, 
of predisposition and possible future development of cognitive 
impairment and AD (46). A prospective actigraphy study led in a 
cohort of 1282 healthy women showed higher incidence of MCI 
and dementia in women with decreased circadian activity rhythm 
amplitude at follow up (approximately 5 years later). Reductions in 
total melatonin (the molecule that controls night-day cycle) levels 
are more profound in AD than in normally aging individuals, 
as showed in a post-mortem study (47–49). Melatonin showed 
protective anti-amyloidogenic effects in vitro and, interestingly, 
was found to be decreased in early (even preclinical) stages of the 
disease, both in total levels and width of the circadian oscillations 
(49, 50). These findings were supported by the observation of a 
decrease in the number of melatonin receptor-carrying neurons 
in the SCN in late-stage AD, alongside with a decrease of volume 
and total cell count in the whole SCN itself (51, 52). Moreover, the 
expression of “clock genes” is altered in the brain of AD patients, 
reflecting the disruption of the master control by the SCN (53). 
These alterations in circadian rhythms were demonstrated in 
animal models transgenic for AD-associated mutations (54).
Circadian disruption can be both a consequence of AD as 
well as worsening factor in AD pathological cascade, suggesting 
a biunivocal relationship between the two (55). On one hand, 
AD pathology can lead to day/night sleep pattern disturbances 
and subsequent poor quality of life; on the other hand, the same 
disturbances can influence the course of AD pathology. Sleep 
deprivation results in increased concentration and accumulation 
of Aβ, in contrast to sleep extension that has the opposite effect. The 
accumulation of Aβ results in increased wakefulness and altered 
sleep pattern, as observed in sleep-restricted animals that showed 
greater Aβ plaque deposition compared to controls (56). Studies 
on orexin, also known as hypocretin, (a molecule that regulates 
wakefulness, strongly implicated in sleep disorders) showed that its 
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release from hypothalamic neurons and the pattern of Aβ in CSF 
have a comparable diurnal fluctuation, and that orexin itself shows 
a circadian rhythm in both AD patients and controls (56, 57). Aβ 
levels are also increased during orexin infusion and decreased 
with an orexin receptor antagonist, indicating a role of orexin and 
sleep-wake cycle disruption in the pathogenesis of AD (52). Low 
CSF Aβ42 levels have been found to be related to lower levels of 
orexin, further suggesting a relationship between AD pathology 
and orexin disturbance (57, 58). A clinical trial on a population 
of healthy middle-aged men confirmed these observations, show-
ing a decrease of 6% in the CSF Aβ42 levels after one night of 
unrestricted sleep and a difference of 75.8 pg/ml between the CSF 
Aβ42 levels of the unrestricted sleep and sleep deprived group (59).
Diurnal variation of CSF AD Biomarkers: 
State of the Art
As previously reported, diurnal variation can be a critical factor 
while studying molecules that can be influenced by circadian 
rhythms, making sampling time a matter of concern. Focusing 
on AD CSF biomarkers, Bateman et al. showed that human CSF 
Aβ levels varied significantly (1.5- to 4-fold) over 36 h (60). The 
Aβ levels showed no significant differences between the hours 
during the daytime period, but an increase during a 36-h period. 
All participants were screened to be in good general health and 
without neurologic diseases. Participants older than 65 were 
non-demented controls, and had a Clinical Dementia Rating of 0. 
Six milliliters of CSF were obtained each hour for 12, 24, or 36 h. 
CSF aliquots were frozen at –80°C immediately after collection 
in 1 ml PP tubes. One milliliter of CSF from each collection hour 
was thawed and Aβ40 and Aβ42 were measured by ELISA. A 
sinusoidal pattern of Aβ levels was observed across participants, 
supposed to be due to time of day, activity, or dynamic changes 
in the production or clearance rate of Aβ in the CNS. The study 
by Bateman was the first to arise the issue of a possible diurnal 
variation of CSF biomarkers that could represent a significant 
obstacle to an accurate diagnosis. However, a previous study 
by Andreasen et al. showed no significant fluctuations of Aβ42 
on repeated lumbar puncture in subjects with AD (61). It may 
be that CSF Aβ variability is decreased in patients with AD 
pathology and amyloid plaques, but has higher fluctuations in 
individuals without plaques. Bjerke et al. also found no diurnal 
variation in 14 psychiatrically and neurologically healthy sub-
jects carrying lumbar catheters due to knee surgery (32); CSF was 
serially collected by lumbar puncture at baseline, after 4–6 h and 
after 24 h. The samples were immediately stored at –80°C. Data 
showed more stable levels with a slight but significant decrease 
in CSF Aβ42 after 4–6  h, which tended to return to baseline 
levels after 24 h. A possible reason for these results is that, as 
opposed to Bateman et al., a smaller CSF volume was taken; this 
could have led to a minor impact on the CSF dynamics. Slats 
et al. also found no diurnal variation in CSF dynamics during 
a 36-h sampling (6  ml per hour) (62). They investigated the 
within-subject variability over 36 h in CSF Aβ and tau proteins, 
in older subjects, and AD patients. Six patients with mild stage 
AD [59–85 years, mini mental state examination (MMSE) 16–26 
range] and six healthy older volunteers (64–77 years) underwent 
insertion of an intrathecal catheter from which 6  ml of CSF 
were collected each hour for 36  h. Variability of CSF Aβ40, 
Aβ42, t-tau, and p-tau concentrations was lower than expected 
and the diurnal variation was not as wide as in the younger 
subjects in Bateman’s study. The most recent study was led by 
Moghekar et al. in a cohort of older mildly symptomatic indi-
viduals to determine whether CSF biomarkers of AD fluctuate 
significantly over time (63). Ten patients suspected of having 
idiopathic normal pressure hydrocephalus or pseudotumor 
cerebri were recruited. Intracranial pressure monitoring and 
CSF drainage represented part of their routine clinical care. 
Most of the patients had relatively modest cognitive problems 
associated with their suspected diagnosis (MMSE score range 
20–30). Clinical diagnoses of dementia and MCI were based on 
informant history as well as cognitive testing, without knowledge 
of AD biomarker levels. All patients underwent insertion of a 
catheter into the lumbar subarachnoid space on the first day of 
hospitalization. After monitoring of intracranial pressure for 
18 h, drainage of CSF was initiated at noon the following day. 
Collection of CSF for analysis started at 6 p.m. on the first day 
of drainage (the second hospital day). Forty milliliters of CSF 
were withdrawn from the lumbar catheter every 6 h for 24 or 
36 consecutive hours and then stored at –80°C until further 
analysis. The levels of Aβ42, Aβ40, total tau, and p-tau, although 
significantly different between the patients, did not fluctuate 
appreciably over time. Significant fluctuations in Aβ did not 
occur in the patients with the highest CSF Aβ levels as well as 
in those with the lowest CSF Aβ levels. This study and the one 
from Bateman et al. have two major differences: age and health 
status of the population and sampling frequency. Population was 
significantly older and with ongoing neurological abnormalities, 
opposed to the young healthy subjects of Bateman’s study; still, 
the role of age is uncertain, since no great differences were found 
in the fluctuations of Aβ42 between the youngest and oldest 
patients in the cohort. The samples were collected every 6  h 
instead of each hour as in Bateman’s study; however, since the 
peak-to-peak variability for Aβ followed a 12-h cycle in the prior 
study, a significant level of variability would have been apparent 
in the latter study. All the results are summarized in Table 3.
Amyloid metabolism is characterized by several critical steps, 
which can cause variability in its CSF levels: production from cleav-
age of amyloid precursor protein (APP), degradation by proteases 
and microglia, and clearance by systemic circulation or lymphatics 
(64). However, up to now, none of these steps justifies the diurnal 
fluctuations of Aβ reported by Bateman, except for the diurnal vari-
ation in transcription, translation of APP, and regulation of the two 
secretases (beta or gamma secretase) that cleave APP to produce 
Aβ (65). In CNS, APP can be cleaved by either the β-secretase 
pathway or the α-secretase pathway: the first is amyloidogenic and 
generates soluble APP-β (sAPPβ) and Aβ; the second one is non-
amyloidogenic and causes the release of soluble APP-α (sAPPα). 
In 2014, Dobrowolska et al. measured APP proteolytic products 
over 36 h in the CSF of cognitively normal and AD individuals, in 
order to clarify the role of APP metabolism in α- and β- pathway 
balance and, consequently, in Aβ diurnal pattern. Diurnal fluctua-
tions were found in sAPPα, sAPPβ, Aβ40, and Aβ42, diminishing 
TABLe 3 | Summary of the effects of diurnal variation on CSF AD biomarkers levels.
Reference 
#
Demographics Population 
size
Samples collection Assay effects of diurnal variation
(60) Non-demented subjects: 
23–78 years old
15 6 ml CSF from lumbar catheter Aβ determined with 
ELISA
Aβ varied significantly, showing an 
increase over a 36 h periodEach hour for 12, 24, or 36 h
CSF frozen at –80°C after collection in 
polypropylene tubes
(32) Healthy subjects 
undergoing knee surgery
14 10–12 ml CSF from lumbar puncture Aβ42 determined with 
xMAP-based assay
No significant diurnal variation, slight 
decrease in Aβ42 levels that tended to 
return to baseline after 24 h
Baseline, after 4–6 h, after 24 h
CSF frozen at –80°C after collection in 
polypropylene tubes
(62) Mild stage AD patients: 
59–85 years old; healthy 
volunteers: 64–77 years 
old
6 + 6 6 ml CSF from intrathecal catheter
During 36 h, each hour
CSF frozen at –80°C after collection in 
polypropylene tubes
Aβ42, t-tau, and p-tau 
determined with xMAP-
based assay. Aβ40 
determined with ELISA
No significant diurnal variation, 
less pronounced circadian pattern 
compared with the one in younger 
subjects
(63) Patients suspected of 
having idiopathic normal 
pressure hydrocephalus 
(n = 9) or pseudotumor 
cerebri (n = 1)
10 40 ml CSF from lumbar catheter
Every 6 h for 24 or 36 consecutive 
hours
CSF frozen at –80°C after collection in 
polypropylene tubes
Aβ42, total tau, and 
p-tau181 determined 
with xMAP-based assay.
No significant diurnal variation
Aβ40 determined with 
ELISA
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